Iovance Biotherapeutics (IOVA) announced that on August 21, 2025, the Company approved the grant of inducement stock options covering an aggregate of 182,370 shares of Iovance’s common stock to 20 new, non-executive employees.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics Amends Sale Agreement with Jefferies
- Iovance Biotherapeutics Gains Health Canada Approval
- Home Depot reports Q2 results, SoftBank invests $2B in Intel: Morning Buzz
- Iovance Biotherapeutics’ Canadian Approval of AMTAGVI: A Milestone in T Cell Therapy and Stock Growth Potential
- Iovance Amtagvi receives Health Canada approval for advanced melanoma